

# Simone Ferrero

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7042454/publications.pdf>

Version: 2024-02-01

107  
papers

3,144  
citations

218592

26  
h-index

168321

53  
g-index

114  
all docs

114  
docs citations

114  
times ranked

4311  
citing authors

#	ARTICLE	IF	CITATIONS
1	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 729-739.	0.8	34
2	A novel phage display based platform for exosome diversity characterization. <i>Nanoscale</i> , 2022, 14, 2998-3003.	2.8	27
3	HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience. <i>Journal of Personalized Medicine</i> , 2022, 12, 285.	1.1	1
4	Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 332-340.	0.8	3
5	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 518-527.	0.8	4
6	A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. <i>Cancers</i> , 2022, 14, 188.	1.7	6
7	Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance. <i>Diagnostics</i> , 2022, 12, 969.	1.3	5
8	Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. <i>Blood</i> , 2022, 140, 1378-1389.	0.6	14
9	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. <i>Leukemia</i> , 2021, 35, 787-795.	3.3	56
10	A brief rituximab, bendamustine, mitoxantrone (R <sup>2</sup> CBM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021, 193, 280-289.	1.2	4
11	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e34-e44.	2.2	29
12	Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia. <i>Journal of Personalized Medicine</i> , 2021, 11, 249.	1.1	6
13	Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. <i>Hematological Oncology</i> , 2021, 39, 293-303.	0.8	6
14	Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports. <i>Journal of Medical Case Reports</i> , 2021, 15, 105.	0.4	2
15	MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation. <i>Diagnostics</i> , 2021, 11, 779.	1.3	14
16	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021, 39, 1214-1222.	0.8	74
17	Application of the Euro Clonality next-generation sequencing based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial. <i>British Journal of Haematology</i> , 2021, 194, 378-381.	1.2	5
18	COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment. <i>HemaSphere</i> , 2021, 5, e592.	1.2	4

#	ARTICLE	IF	CITATIONS
19	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. <i>Bone Marrow Transplantation</i> , 2021, 56, 2606-2609.	1.3	3
20	Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network. <i>HemaSphere</i> , 2021, 5, e639.	1.2	0
21	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. <i>Cancers</i> , 2021, 13, 291.	1.7	17
22	Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. <i>Blood Advances</i> , 2021, 5, 3188-3198.	2.5	2
23	Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2021, 138, 48-48.	0.6	2
24	Letermovir Prophylaxis Versus Pre-Emptive Therapy for Cytomegalovirus after Hematopoietic Stem-Cell Transplantation. <i>Blood</i> , 2021, 138, 4861-4861.	0.6	1
25	<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. <i>Haematologica</i> , 2020, 105, 1604-1612.	1.7	96
26	Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. <i>Journal of Geriatric Oncology</i> , 2020, 11, 37-40.	0.5	14
27	Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 2197-2199.	0.8	5
28	Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. <i>American Journal of Hematology</i> , 2020, 95, 1473-1478.	2.0	7
29	Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 698-704.	0.8	3
30	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. <i>American Journal of Hematology</i> , 2020, 95, 1553-1561.	2.0	18
31	ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study. <i>American Journal of Hematology</i> , 2020, 95, 1030-1037.	2.0	6
32	Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. <i>HemaSphere</i> , 2020, 4, e302.	1.2	10
33	Droplet Digital PCR Assay for <i>MYD88</i> <sup>L265P</sup> : Clinical Applications in Waldenström Macroglobulinemia. <i>HemaSphere</i> , 2020, 4, e324.	1.2	3
34	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. <i>Cell Reports Medicine</i> , 2020, 1, 100158.	3.3	18
35	Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network. <i>HemaSphere</i> , 2020, 4, e347.	1.2	36
36	Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2020, 136, 16-17.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Influenza Vaccination in Asplenia: Improving Quality of Care in Time of Coronavirus. <i>Blood</i> , 2020, 136, 39-40.	0.6	0
38	Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial. <i>Blood</i> , 2020, 136, 29-30.	0.6	16
39	THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI: A PROSPECTIVE COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) OF 1353 ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 248-250.	0.8	4
40	Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. <i>Blood</i> , 2019, 134, 798-801.	0.6	53
41	Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. <i>Hematological Oncology</i> , 2019, 37, 368-374.	0.8	13
42	OUTCOMES IN FIRST RELAPSED/REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY. <i>Hematological Oncology</i> , 2019, 37, 46-47.	0.8	3
43	RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.. <i>Hematological Oncology</i> , 2019, 37, 153-154.	0.8	19
44	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. <i>Haematologica</i> , 2019, 104, e410-e414.	1.7	5
45	PS1312 QPCR, MFC AND DDPCR: COMPARISON ON MRD SAMPLES FROM THREE PROSPECTIVE TRIALS OF THE EUROPEAN MCL NETWORK. <i>HemaSphere</i> , 2019, 3, 599.	1.2	1
46	MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL). <i>HemaSphere</i> , 2019, 3, e305.	1.2	4
47	FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY. <i>Hematological Oncology</i> , 2019, 37, 224-225.	0.8	7
48	Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-15.	1.0	7
49	Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. <i>British Journal of Haematology</i> , 2019, 185, 940-944.	1.2	49
50	ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study. <i>Blood</i> , 2019, 134, 1565-1565.	0.6	1
51	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. <i>Haematologica</i> , 2018, 103, 849-856.	1.7	21
52	Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. <i>Oncologist</i> , 2018, 23, 454-460.	1.9	22
53	Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders. <i>Methods in Molecular Biology</i> , 2018, 1768, 229-256.	0.4	24
54	Highly sensitive MYD88 <sup>L265P</sup> mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. <i>Haematologica</i> , 2018, 103, 1029-1037.	1.7	61

#	ARTICLE	IF	CITATIONS
55	Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up. British Journal of Haematology, 2018, 181, 693-695.	1.2	1
56	Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment. Current Treatment Options in Oncology, 2018, 19, 71.	1.3	6
57	New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies. Journal of Clinical Medicine, 2018, 7, 288.	1.0	24
58	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood, 2018, 132, 2115-2124.	0.6	232
59	A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. Biology of Blood and Marrow Transplantation, 2018, 24, 1814-1822.	2.0	18
60	ParallelHashClone: A Parallel Implementation of HashClone Suite for Clonality Assessment from NGS Data. , 2018, , .		0
61	Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program. Hematological Oncology, 2018, 36, 689-692.	0.8	5
62	FicollâChypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis. International Journal of Laboratory Hematology, 2018, 40, 201-208.	0.7	8
63	Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification. Blood, 2018, 132, 920-920.	0.6	8
64	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. Oncotarget, 2018, 9, 23443-23450.	0.8	12
65	Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. Haematologica, 2017, 102, e203-e206.	1.7	21
66	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematology, the, 2017, 4, e15-e23.	2.2	106
67	Data quality improvement of a multicenter clinical trial dataset. , 2017, 2017, 1190-1193.		6
68	KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL. Hematological Oncology, 2017, 35, 94-95.	0.8	2
69	NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION (TLA) NGS STRATEGY. Hematological Oncology, 2017, 35, 151-151.	0.8	1
70	OBINUTUZUMAB-MINICHOP FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. A STUDY OF THE FONDAZIONE ITALIANA LINFOMI. Hematological Oncology, 2017, 35, 183-184.	0.8	0
71	MANTLE CELL LYMPHOMA OF MUCOSAâ€ASSOCIATED LYMPHOID TISSUE: A RETROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK. Hematological Oncology, 2017, 35, 202-203.	0.8	0
72	Minimal residual disease by next-generation sequencing in mantle cell lymphoma: The bioinformatics tool <scp>HashClone</scp>. Hematological Oncology, 2017, 35, 299-300.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?. <i>Haematologica</i> , 2017, 102, 1133-1136.	1.7	20
74	HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data. <i>BMC Bioinformatics</i> , 2017, 18, 516.	1.2	10
75	Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. <i>Oncotarget</i> , 2017, 8, 5924-5935.	0.8	33
76	Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. <i>Annals of Hematology</i> , 2016, 95, 1107-1114.	0.8	25
77	Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?. <i>Oncologist</i> , 2016, 21, 1107-1112.	1.9	33
78	Novel <i>CALR</i> somatic mutations in essential thrombocythaemia. <i>British Journal of Haematology</i> , 2016, 173, 797-801.	1.2	4
79	The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?. <i>Haematologica</i> , 2016, 101, 104-114.	1.7	31
80	Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial. <i>Leukemia</i> , 2016, 30, 984-987.	3.3	11
81	Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2016, 30, 1211-1214.	3.3	33
82	Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience. <i>Haematologica</i> , 2015, 100, 706-708.	1.7	5
83	Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2637-2642.	0.6	55
84	Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. <i>Leukemia</i> , 2015, 29, 689-695.	3.3	75
85	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 652-660.	1.2	115
86	Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms. <i>Blood</i> , 2015, 126, 1411-1411.	0.6	1
87	The Challenge of Treating Elderly Patients with Mantle Cell Lymphoma. , 2015, , 143-168.		0
88	Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. <i>Leukemia</i> , 2014, 28, 1299-1307.	3.3	257
89	How to manage mantle cell lymphoma. <i>Leukemia</i> , 2014, 28, 2117-2130.	3.3	44
90	New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?. <i>Clinical Cancer Research</i> , 2014, 20, 5194-5206.	3.2	31

#	ARTICLE	IF	CITATIONS
91	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2014, 123, 1293-1296.	0.6	345
92	How to treat old MCL patients: one size fits it all?. <i>Blood</i> , 2014, 124, 1207-1208.	0.6	7
93	Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. <i>Annals of Hematology</i> , 2013, 92, 1503-1511.	0.8	19
94	The current therapeutic scenario for relapsed mantle cell lymphoma. <i>Current Opinion in Oncology</i> , 2013, 25, 452-462.	1.1	5
95	Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. <i>Blood</i> , 2012, 119, 2066-2073.	0.6	217
96	Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. <i>Leukemia</i> , 2012, 26, 1081-1090.	3.3	59
97	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. <i>Haematologica</i> , 2012, 97, 849-853.	1.7	14
98	Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 788-788.	0.6	1
99	High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma. <i>Blood</i> , 2012, 120, 4204-4204.	0.6	0
100	Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. <i>Hematological Oncology</i> , 2011, 29, 167-176.	0.8	36
101	Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2077-2084.	0.8	246
102	Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPi) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy. <i>Blood</i> , 2010, 116, 1784-1784.	0.6	1
103	IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin. <i>Blood</i> , 2010, 116, 2951-2951.	0.6	0
104	Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.. <i>Blood</i> , 2010, 116, 3375-3375.	0.6	2
105	Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009, 23, 1062-1072.	3.3	97
106	Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.. <i>Blood</i> , 2009, 114, 960-960.	0.6	3
107	Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP.. <i>Blood</i> , 2009, 114, 99-99.	0.6	10